Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell
• argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
Dow Jumps 250 Points; US Jobless Claims Increase Last Week
U.S. stocks traded higher this morning, with the Dow Jones jumping around 250 points on Thursday.
The Dow traded up 0.75% to 34,204.99 while the NASDAQ rose 1.15% to 12,047.28. The S&P 500 also rose, gaining, 0.75% to 4,148.69.
Nasdaq Tumbles 150 Points; Crude Oil Up 1.5%
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 150 points on Wednesday.
The Dow traded down 0.27% to 34,063.42 while the NASDAQ fell 1.33% to 11,952.51. The S&P 500 also fell, dropping, 0.80% to 4,130.55.
INmune Bio, Inc. Announces Pre-Clinical Data That Support A Pioneering Approach To Treating Duchenne Muscular Dystrophy
INmune Bio, Inc.(NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, in collaboration with
INmune Bio Data At ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence Of Cancer Killing Memory Like NK Cells In Patients With AML/MDS Following Treatment With INKmune
INmune Bio, Inc. (NASDAQ:INMB) ("INMB" or "the Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system
INmune Bio Reports Combination Therapy With INB03™ Overcomes Resistance To Trastuzumab-Deruxtecan In MUC4 Expressing HER2+ Breast Cancer
Neutralizing soluble TNF with INB03™ overcomes resistance to trastuzumab-deruxtecan in MUC4 expressing HER2+breast cancer.
Combination therapy of INB03™ and trastuzumab-deruxtecan presented at the 45th
Recap: INmune Bio Q2 Earnings
INmune Bio (NASDAQ:INMB) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
INmune Bio beat estimated earnings by 24.0%, reporting an EPS of $-0.38 versus an estimate of $-0.5.
BTIG Maintains Buy on INmune Bio, Lowers Price Target to $14
BTIG analyst Thomas Shrader maintains INmune Bio (NASDAQ:INMB) with a Buy and lowers the price target from $31 to $14.
The Daily Biotech Pulse: INmune Bio’s Planned Alzheimer’s Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: